Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

December 10, 2023

Study Completion Date

June 4, 2025

Conditions
Osteoarthritis, Knee
Interventions
DRUG

Bone marrow mesenchymal stem cells

The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.

DRUG

hyaluronic acid

(60 mg/3 mL hyaluronic acid \[HA\])

Trial Locations (2)

112

Taipei Veterans General Hospital, Taipei

116

Taipei Municipal Wangfang Hospital (Managed by Taipei Medical University), Taipei

All Listed Sponsors
collaborator

A2 Healthcare Taiwan Corporation

INDUSTRY

lead

Taiwan Bio Therapeutics Inc.

INDUSTRY

NCT05027581 - Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA) | Biotech Hunter | Biotech Hunter